DT
HealthMore in Health→
Early liver transplant trial hints at a future with less lifelong immunosuppression
A first-in-human trial at UPMC and the University of Pittsburgh suggests some living donor liver transplant recipients can be safely weaned off immunosuppressive drugs after donor-derived immune cell priming.
Key Takeaways
- Researchers infused donor-derived immune cells before living donor liver transplantation.
- Some recipients have stayed off immunosuppressive drugs for more than three years.
DE
DT Editorial Team··via medicalxpress.com